FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2142016013> ?p ?o ?g. }

• W2142016013 endingPage "558" @default.
• W2142016013 startingPage "549" @default.
• W2142016013 abstract "BackgroundLong-term hormone therapy alone is standard care for metastatic or high-risk, non-metastatic prostate cancer. STAMPEDE—an international, open-label, randomised controlled trial—uses a novel multiarm, multistage design to assess whether the early additional use of one or two drugs (docetaxel, zoledronic acid, celecoxib, zoledronic acid and docetaxel, or zoledronic acid and celecoxib) improves survival in men starting first-line, long-term hormone therapy. Here, we report the preplanned, second intermediate analysis comparing hormone therapy plus celecoxib (arm D) with hormone therapy alone (control arm A).MethodsEligible patients were men with newly diagnosed or rapidly relapsing prostate cancer who were starting long-term hormone therapy for the first time. Hormone therapy was given as standard care in all trial arms, with local radiotherapy encouraged for newly diagnosed patients without distant metastasis. Randomisation was done using minimisation with a random element across seven stratification factors. Patients randomly allocated to arm D received celecoxib 400 mg twice daily, given orally, until 1 year or disease progression (including prostate-specific antigen [PSA] failure). The intermediate outcome was failure-free survival (FFS) in three activity stages; the primary outcome was overall survival in a subsequent efficacy stage. Research arms were compared pairwise against the control arm on an intention-to-treat basis. Accrual of further patients was discontinued in any research arm showing safety concerns or insufficient evidence of activity (lack of benefit) compared with the control arm. The minimum targeted activity at the second intermediate activity stage was a hazard ratio (HR) of 0·92. This trial is registered with ClinicalTrials.gov, number NCT00268476, and with Current Controlled Trials, number ISRCTN78818544.Findings2043 patients were enrolled in the trial from Oct 17, 2005, to Jan 31, 2011, of whom 584 were randomly allocated to receive hormone therapy alone (control group; arm A) and 291 to receive hormone therapy plus celecoxib (arm D). At the preplanned analysis of the second intermediate activity stage, with 305 FFS events (209 in arm A, 96 in arm D), there was no evidence of an advantage for hormone therapy plus celecoxib over hormone therapy alone: HR 0·94 (95% CI 0·74–1·20). 2-year FFS was 51% (95% CI 46–56) in arm A and 51% (95% CI 43–58) in arm D. There was no evidence of differences in the incidence of adverse events between groups (events of grade 3 or higher were noted at any time in 123 [23%, 95% CI 20–27] patients in arm A and 64 [25%, 19–30] in arm D). The most common grade 3–5 events adverse effects in both groups were endocrine disorders (55 [11%] of patients in arm A vs 19 [7%] in arm D) and musculoskeletal disorders (30 [6%] of patients in arm A vs 15 [6%] in arm D). The independent data monitoring committee recommended stopping accrual to both celecoxib-containing arms on grounds of lack of benefit and discontinuing celecoxib for patients currently on treatment, which was endorsed by the trial steering committee.InterpretationCelecoxib 400 mg twice daily for up to 1 year is insufficiently active in patients starting hormone therapy for high-risk prostate cancer, and we do not recommend its use in this setting. Accrual continues seamlessly to the other research arms and follow-up of all arms will continue to assess effects on overall survival.FundingCancer Research UK, Pfizer, Novartis, Sanofi-Aventis, Medical Research Council (London, UK)." @default.
• W2142016013 created "2016-06-24" @default.
• W2142016013 creator A5007452018 @default.
• W2142016013 creator A5011233738 @default.
• W2142016013 creator A5014097745 @default.
• W2142016013 creator A5018620241 @default.
• W2142016013 creator A5018743880 @default.
• W2142016013 creator A5022329395 @default.
• W2142016013 creator A5025921361 @default.
• W2142016013 creator A5027212039 @default.
• W2142016013 creator A5030105260 @default.
• W2142016013 creator A5032518609 @default.
• W2142016013 creator A5033521569 @default.
• W2142016013 creator A5043586804 @default.
• W2142016013 creator A5048994559 @default.
• W2142016013 creator A5059261043 @default.
• W2142016013 creator A5062184568 @default.
• W2142016013 creator A5062742458 @default.
• W2142016013 creator A5065195021 @default.
• W2142016013 creator A5079820994 @default.
• W2142016013 creator A5088732876 @default.
• W2142016013 date "2012-05-01" @default.
• W2142016013 modified "2023-10-15" @default.
• W2142016013 title "Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial" @default.
• W2142016013 cites W1648593433 @default.
• W2142016013 cites W1981989535 @default.
• W2142016013 cites W2023189718 @default.
• W2142016013 cites W2052720577 @default.
• W2142016013 cites W2060928649 @default.
• W2142016013 cites W2080439368 @default.
• W2142016013 cites W2103959341 @default.
• W2142016013 cites W2110534364 @default.
• W2142016013 cites W2117227343 @default.
• W2142016013 cites W2117511763 @default.
• W2142016013 cites W2117580825 @default.
• W2142016013 cites W2118250868 @default.
• W2142016013 cites W2118612714 @default.
• W2142016013 cites W2119504728 @default.
• W2142016013 cites W2120292596 @default.
• W2142016013 cites W2123526148 @default.
• W2142016013 cites W2132850027 @default.
• W2142016013 cites W2132892424 @default.
• W2142016013 cites W2138381757 @default.
• W2142016013 cites W2139232028 @default.
• W2142016013 cites W2139295697 @default.
• W2142016013 cites W2146599397 @default.
• W2142016013 cites W2151523134 @default.
• W2142016013 cites W2151981428 @default.
• W2142016013 cites W2153258256 @default.
• W2142016013 cites W2155697876 @default.
• W2142016013 cites W2157509061 @default.
• W2142016013 cites W2158639339 @default.
• W2142016013 cites W2158968701 @default.
• W2142016013 cites W2165429160 @default.
• W2142016013 cites W2165631552 @default.
• W2142016013 cites W2165782799 @default.
• W2142016013 cites W2172161665 @default.
• W2142016013 cites W2336169581 @default.
• W2142016013 cites W4211149743 @default.
• W2142016013 doi "https://doi.org/10.1016/s1470-2045(12)70088-8" @default.
• W2142016013 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3398767" @default.
• W2142016013 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22452894" @default.
• W2142016013 hasPublicationYear "2012" @default.
• W2142016013 type Work @default.
• W2142016013 sameAs 2142016013 @default.
• W2142016013 citedByCount "97" @default.
• W2142016013 countsByYear W21420160132012 @default.
• W2142016013 countsByYear W21420160132013 @default.
• W2142016013 countsByYear W21420160132014 @default.
• W2142016013 countsByYear W21420160132015 @default.
• W2142016013 countsByYear W21420160132016 @default.
• W2142016013 countsByYear W21420160132017 @default.
• W2142016013 countsByYear W21420160132018 @default.
• W2142016013 countsByYear W21420160132019 @default.
• W2142016013 countsByYear W21420160132020 @default.
• W2142016013 countsByYear W21420160132021 @default.
• W2142016013 countsByYear W21420160132022 @default.
• W2142016013 countsByYear W21420160132023 @default.
• W2142016013 crossrefType "journal-article" @default.
• W2142016013 hasAuthorship W2142016013A5007452018 @default.
• W2142016013 hasAuthorship W2142016013A5011233738 @default.
• W2142016013 hasAuthorship W2142016013A5014097745 @default.
• W2142016013 hasAuthorship W2142016013A5018620241 @default.
• W2142016013 hasAuthorship W2142016013A5018743880 @default.
• W2142016013 hasAuthorship W2142016013A5022329395 @default.
• W2142016013 hasAuthorship W2142016013A5025921361 @default.
• W2142016013 hasAuthorship W2142016013A5027212039 @default.
• W2142016013 hasAuthorship W2142016013A5030105260 @default.
• W2142016013 hasAuthorship W2142016013A5032518609 @default.
• W2142016013 hasAuthorship W2142016013A5033521569 @default.
• W2142016013 hasAuthorship W2142016013A5043586804 @default.
• W2142016013 hasAuthorship W2142016013A5048994559 @default.
• W2142016013 hasAuthorship W2142016013A5059261043 @default.
• W2142016013 hasAuthorship W2142016013A5062184568 @default.
• W2142016013 hasAuthorship W2142016013A5062742458 @default.
• W2142016013 hasAuthorship W2142016013A5065195021 @default.
• W2142016013 hasAuthorship W2142016013A5079820994 @default.
• W2142016013 hasAuthorship W2142016013A5088732876 @default.

• next